Studies on Plasmepsins I and II from the Malarial Parasite Plasmodium falciparum and their exploitation as drug targets

Moon, Richard P., Bur, Daniel, Loetscher, Hansruedi, D'Arcy, Allan, Tyas, Lorraine, Oefner, Christian, Grueninger-Leitch, Fiona, Mona, Daniel, Rupp, Katherina, Dorn, Arnulf, Matile, Hugues, Certa, Ulrich, Berry, Colin ORCID: https://orcid.org/0000-0002-9943-548X, Kay, John and Ridley, Robert G. 1998. Studies on Plasmepsins I and II from the Malarial Parasite Plasmodium falciparum and their exploitation as drug targets. Advances in Experimental Medicine and Biology 436 , pp. 397-406. 10.1007/978-1-4615-5373-1_56

Full text not available from this repository.

Abstract

Malaria is one of the major diseases of the world. Between 2 to 3 million deaths occur each year, mainly children under 5 years of age living in sub-Saharan Africa. Up to 300 million people are infected at any given time and up to 2 billion people (close to half the world population) live in malarious areas and are at risk of infection. The most virulent of the four malaria species which infect humans is Plasmodium falciparum and the spread of resistance by this species to the available drugs, such as chloroquine, has resulted in a critical world health situation with a desperate need to develop new drugs.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Subjects:	Q Science > QR Microbiology
Publisher:	Springer
ISSN:	0065-2598
Last Modified:	27 Oct 2022 09:13
URI:	https://orca.cardiff.ac.uk/id/eprint/64820

Citation Data

Cited 18 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item